Skip to content

Company

Ono Pharma

Structure of Ono Pharma

Ono Pharma

Company

2 connections
UpstreamSupply and dependency
PeersCompetition and partners
Relationship began2026
Ono PharmaCompany · 2 connections
Layer 1

UpstreamSupply and dependency1

PeersCompetition and partners1

Relations

Arrows show the direction of the relationship. Filter to focus on a business area.

  • Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-10-08 16:00
      Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states
      View source
  • Biohavenagreement with →Ono Pharma
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-10-08 16:00
      Under the terms of the agreement, Ono will obtain an exclusive license to develop and commercialize BHV-1300, BHV-1310, and BHV-1320
      View source

Showing 1 to 2 of 2

Claims

Read the assertion alongside its sources. Expand a row to inspect the evidence.

FactEvidence 1
agreement withBiohaven

Under the terms of the agreement, Ono will obtain an exclusive license to develop and commercialize BHV-1300, BHV-1310, and BHV-1320

PR Newswire news releases · 2026-10-08 16:00

View evidence
  • CompanyPR Newswire news releases2026-10-08 16:00
    Under the terms of the agreement, Ono will obtain an exclusive license to develop and commercialize BHV-1300, BHV-1310, and BHV-1320
    View source
FactEvidence 1

Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states

PR Newswire news releases · 2026-10-08 16:00

View evidence
  • CompanyPR Newswire news releases2026-10-08 16:00
    Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states
    View source

Showing 1 to 2 of 2

Market and valuation

Valuation data is available on Pro and Research.

Included in Pro

Not available: Company signals · Financials · Filings · Guidance